Silexion Therapeutics Corp 8-K

What Happened
Silexion Therapeutics Corp (SLXN) filed a Current Report on Form 8-K on March 24, 2026 (Item 7.01) to disclose a press release announcing that the Israeli Ministry of Health approved the company to initiate a Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer. The press release titled “Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer” is furnished as Exhibit 99.1 to the Form 8-K.

Key Details

• Press release and Form 8-K filed on March 24, 2026 (Item 7.01, Regulation FD disclosure).
• Approval granted by the Israeli Ministry of Health to initiate a Phase 2/3 trial of SIL204.
• Indication: locally advanced pancreatic cancer.
• The press release is furnished as Exhibit 99.1 to the Form 8-K.

Why It Matters
This is a regulatory and development milestone for Silexion’s lead candidate, SIL204, moving the program into a combined Phase 2/3 study for a serious oncology indication. For investors, the filing signals progress in the company’s clinical pipeline and is material information recently disclosed under Regulation FD; further clinical, enrollment, and outcome announcements will be important to monitor.